73 articles in this topic
A Phase 3 trial investigates whether the GLP-1 drug liraglutide can slow cognitive decline in T2DM patients at elevated Alzheimer's risk.
A pilot RCT tested whether a smartphone app could improve quality of life and treatment adherence in HIV-positive patients aged 60+.
A Phase 1 trial examines whether Botulinum toxin in the glabella and forehead lifts mood and self-appearance satisfaction in returning Botox patients.
Applied Cognition tests a wearable device that tracks glymphatic function overnight, comparing it to MRI, EEG, and blood biomarkers.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
A landmark RCT tests whether hearing aids can protect brain health in 977 older adults over 3 years.
A completed trial tests EGCG combined with diet, exercise, and cognitive training to slow decline in ApoE4 carriers with early warning signs.
A completed RCT tests whether treating insomnia with CBT-I can improve cognition and slow amyloid buildup in adults aged 60–85.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
A completed Canadian platform trial enrolls 354 at-risk adults in a multidomain online brain health program targeting dementia prevention.
A completed pharmacokinetic study tracks NAD precursors NR and NMN from bloodstream to brain, filling a critical gap in human data.
A completed RCT tested whether a CBT-based smartphone app reduces moderate depression versus an active placebo in 158 participants; outcomes are not reported in the registration record.
